Tamoxifen is a medicine used to treat breast cancer. It works by blocking the effects of estrogen in certain tissues. It's often used after surgery for breast cancer or to prevent cancer from coming back.
Every report comes from a Lived member, sent anonymously.
Have you tried Tamoxifen for Breast Cancer?
Tamoxifen is a hormone-blocking medicine taken by mouth to treat and prevent breast cancer that depends on estrogen to grow. It is used for cancers that test estrogen receptor-positive, meaning the tumor cells carry receptors that estrogen attaches to. When those receptors are absent, tamoxifen offers little benefit. Most people take generic tamoxifen tablets. Soltamox is a liquid form, and Nolvadex, the original brand, is no longer sold in the US. After surgery for early breast cancer, tamoxifen is used to lower the chance that the cancer comes back and to reduce the risk of a new cancer in the other breast. It also treats breast cancer that has spread to other parts of the body (metastatic breast cancer), in both women and men. Tamoxifen works before and after menopause. That matters because aromatase inhibitors, the other main group of hormone pills, are used mainly after menopause, or before it only together with treatment that shuts down the ovaries. Men with early hormone-sensitive breast cancer are usually treated with tamoxifen first. Tamoxifen also has two preventive uses. For women with ductal carcinoma in situ (DCIS), abnormal cells confined to the milk ducts, it lowers the risk of a later invasive cancer after surgery and radiation. For women 35 and older at high risk of breast cancer, judged from factors such as family history and past biopsy findings, it lowers the chance of developing the disease. Before menopause, it is the standard medicine for this purpose in women who have finished having children. In these preventive settings the decision rests on a careful weighing of benefits and risks, because there is no invasive cancer to treat.
Estrogen acts as a growth signal for many breast cancers. It attaches to estrogen receptors in the cancer cells and switches on activity that helps them grow. Tamoxifen competes with estrogen for those same receptors, so in breast tissue the growth signal is weakened. This can slow or stop the growth of hormone-sensitive cancer cells, and it makes it less likely that stray cells left after surgery will grow into a recurrence. Tamoxifen belongs to a group called selective estrogen receptor modulators, or SERMs, because it does not block estrogen everywhere. In some tissues, such as bone and the lining of the uterus, it acts more like estrogen. This mixed action explains several of its effects. After menopause it has not been shown to cause bone loss, but before menopause it has been linked to some loss of bone density in the hip and spine. Its estrogen-like action on the uterus is thought to underlie its higher risk of uterine changes, including uterine cancer.
Tamoxifen is usually taken once a day. The standard dose for early breast cancer, DCIS and risk reduction is 20 mg a day. For metastatic cancer the dose can be 20 to 40 mg, with amounts above 20 mg split into a morning and an evening dose. Tablets come in 10 mg and 20 mg strengths. Soltamox liquid contains 20 mg in every 10 mL and should be measured with the dosing cup that comes with it. An opened bottle is thrown away after three months. The length of treatment is a central part of the plan. After surgery for early breast cancer, tamoxifen is typically taken for 5 to 10 years. Some people take it for the whole period, and others switch to an aromatase inhibitor partway through once they are past menopause. For DCIS and for risk reduction, the usual course is 5 years. The benefit builds from steady treatment over years, so taking it every day matters. If a dose is missed, the usual advice is to take it when remembered unless the next dose is nearly due, and never to take two doses at once. Stopping early should be a decision made with the care team.
Hot flashes are the most common side effect, and for some people they are frequent or severe. Vaginal discharge, irregular or missed periods in those who still menstruate, nausea, swelling from fluid retention and mood changes are also common. In metastatic cancer, a short flare of bone or tumor pain can happen soon after starting and usually settles quickly. Because tamoxifen acts like estrogen on the uterus, it can cause polyps and thickening of the uterine lining and raises the risk of uterine cancer. Abnormal vaginal bleeding, a change in vaginal discharge, or pelvic pain or pressure should be reported to the care team promptly, whether it happens during treatment or after it has ended. A yearly gynecologic exam is recommended, but routine tests of the uterine lining in people without symptoms have not been shown to help. Tamoxifen also raises the risk of blood clots, more so when it is given at the same time as chemotherapy. Pain, tenderness or swelling in one or both legs should be reported to the care team right away. Call 911 for sudden chest pain, sudden shortness of breath or coughing up blood, which can signal a clot in the lungs. Also call 911 for sudden weakness or numbness on one side of the body, trouble speaking or sudden loss of vision, which can signal a stroke. Tamoxifen increases the chance of cataracts and other eye problems, so any change in vision is worth reporting.
Tamoxifen carries an FDA boxed warning, the agency's most prominent type of warning, about uterine cancer, stroke and blood clots in the lungs, some of which have been fatal. For most people already diagnosed with breast cancer, the benefit of lowering the chance of recurrence outweighs these risks. For people taking it to prevent cancer, after DCIS or because of high risk, the balance is closer and depends on their baseline breast cancer risk, age and personal clot risk. In those preventive uses, tamoxifen is not given to anyone who has had a deep vein clot or a clot in the lungs, or who needs the blood thinner warfarin. When tamoxifen treats breast cancer, a past clot calls for a careful discussion rather than an automatic no, and anyone also taking warfarin needs closer blood testing because tamoxifen can strongly increase warfarin's effect. Tamoxifen can harm a developing baby. A pregnancy test is done before starting, and anyone who could become pregnant should use effective non-hormonal birth control during treatment and for 2 months after the last dose. Hormonal methods, including pills, patches, implants and hormone-releasing intrauterine devices, should not be used. Irregular or absent periods on tamoxifen do not mean pregnancy is impossible. Breastfeeding is not recommended during treatment or for 3 months afterward. The body converts tamoxifen into more potent active forms using a liver enzyme called CYP2D6. Some antidepressants, such as paroxetine, strongly block this enzyme. Studies disagree on whether that lowers tamoxifen's effectiveness, but antidepressants are often used for mood or hot flashes during treatment, so it is worth asking whether a different one would be better. Sertraline, citalopram and venlafaxine are among those doctors may suggest. The antibiotic rifampin lowers tamoxifen levels and should not be combined with it. Tell the care team and pharmacist about every prescription, over-the-counter medicine and supplement.
For most people, tamoxifen does not produce a benefit they can feel. Its value shows up as a lower chance of cancer returning or developing over many years. In large analyses of trials, about five years of tamoxifen for estrogen receptor-positive early breast cancer lowered the risk of recurrence and of death from breast cancer over the following 15 years. In the main prevention trial in high-risk women, it reduced new invasive breast cancers by about 44 percent over roughly four years, mostly small estrogen receptor-positive tumors, although it did not change overall survival. How much this means for one person depends on her starting risk: the higher that risk, the more cancers are prevented. Because the benefit depends on years of treatment while side effects are felt day to day, it helps to raise problems early rather than stop quietly. Many side effects can be eased by adjusting the plan or switching to another hormone therapy, and stopping is a choice best made with full information about what it gives up. Follow-up usually includes a yearly gynecologic exam for those with a uterus, periodic blood tests of liver function and blood counts (rare but serious liver problems and low blood counts can occur), and attention to eye symptoms. People with metastatic cancer in the bones may have their calcium levels checked in the first weeks, because high calcium can develop soon after starting.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Tamoxifen, what you've noticed, or ask the community a question.